Clinical Trial Update: Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine. [Phase 2]

View source ↗

Summary

Phase 2 safety and immunogenicity study of GlaxoSmithKline's 10-valent pneumococcal conjugate vaccine has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis A

Drugs mentioned

• Synflorix (10-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis A | Phase 2 | Status: COMPLETED